Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Candel Therapeutics's ebitda for the twelve months ending Jun 30, 2023 was -$35.39M. For fiscal 2022 it was -$33.94M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$33.94M | – |
| FY2021 | Dec 31, 2021 | -$25.49M | – |
| FY2020 | Dec 31, 2020 | -$13.72M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$9.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.12M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.60M | – |
See a number that looks wrong?